The latest biotech news

News and Trends 18 Jul 2023

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its fatty acid ligand conjugated oligonucleotide (FALCON) platform, has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma’s lead […]

July 18, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 18 Jul 2023

FDA approves Beyfortus ahead of 2023-24 RSV season

The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The approval also covers children up to 24 months of age who remain vulnerable to severe […]

July 18, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Hope for Alzheimer’s patients after Lilly drug results

Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […]

July 17, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Westlake launches $450M fund for LA biotechs

Westlake Village BioPartners has launched its third fund of $450 million to incubate and grow early stage next-generation biotechnology companies in the Los Angeles region and beyond. The new fund will be managed by founding managing director Beth Seidenberg, managing director Mira Chaurushiya, and David Allison, who was recently appointed managing director. “This new fund […]

July 17, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Lilly boosts obesity portfolio with Versanis Bio acquisition

Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […]

July 17, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Jul 2023

Life saved: AI discovers existing drug works for rare disease

A patient’s life was saved after researchers at the University of Pennsylvania, Castleman Disease Collaborative Network, Medidata, and Every Cure, used artificial intelligence to use an existing drug to treat idiopathic multicentric Castleman disease (iMCD). Every Cure and its partners are developing medical databases and AI algorithms to unlock new uses for existing medicines across […]

July 14, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 14 Jul 2023

TME Pharma provides positive glioblastoma trial results

TME Pharma N.V. has announced a positive clinical update on the best response to therapy, reporting one patient achieving complete response in the GLORIA expansion arm evaluating NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab, in first-line glioblastoma. TME Pharma is a biotechnology company focused on developing novel […]

July 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 14 Jul 2023

BioGeneration Ventures closes BGV Fund V at €150M

BioGeneration Ventures (BGV), an early-stage venture capital company in European biopharma, has closed its BGV V fund at €150 million ($167.9 million), its largest fund since launching its first fund in 2006. BGV V was oversubscribed, with demand from both existing and new investors, with existing investors Eli Lilly and Company, Novo Holdings and Bristol […]

July 14, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Jul 2023

Calliditas reveals ‘encouraging results’ from head and neck cancer trial

Calliditas Therapeutics AB has announced interim data from its proof-of-concept phase 2 trial in patients with squamous cell carcinoma of the head and neck (SCCHN) with its lead NOX 1 and 4 inhibitor product candidate, setanaxib. The analysis reflects encouraging early clinical progression-free survival (PFS) results and is supportive of the presumed anti fibrotic mode […]

July 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 13 Jul 2023

Partnership to progress neurodegenerative disorder treatments

IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]

July 13, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 13 Jul 2023

Gene therapy company EG 427 raises €18M

EG 427, a French biotechnology company leading the development of pinpoint DNA medicine solutions, has announced the final closing of a Series A financing. The gene therapy company raised an additional €5 million ($5.6 million) in the final closing from a combination of existing investors and new family office investors, bringing the total raised in […]

July 13, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

New venture capital company Biovance Capital Partners launches

Bionova Capital has started a new venture capital company, Biovance Capital Partners. Bionova Capital is a healthcare-focused investor in early-stage life science companies across Europe. Founded in 2015, Bionova Capital actively manages a portfolio of five companies, two in Portugal, two in the U.K., and one in Spain. The new, independent company is fully owned […]

July 12, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

FDA approves Beyfortus ahead of 2023-24 RSV season

Hope for Alzheimer’s patients after Lilly drug results

Westlake launches $450M fund for LA biotechs

Lilly boosts obesity portfolio with Versanis Bio acquisition

Life saved: AI discovers existing drug works for rare disease

TME Pharma provides positive glioblastoma trial results

BioGeneration Ventures closes BGV Fund V at €150M

Calliditas reveals ‘encouraging results’ from head and neck cancer trial

Partnership to progress neurodegenerative disorder treatments

Gene therapy company EG 427 raises €18M

New venture capital company Biovance Capital Partners launches

Subscribe to our newsletter to get the latest biotech news!